Title:
MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES
Document Type and Number:
WIPO Patent Application WO/2015/175874
Kind Code:
A3
Abstract:
The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgGl), that have modifications of one or more of amino acid residues in at least the CH3 domain.
More Like This:
Inventors:
TSUI PING (US)
BORROK MARTIN (US)
DALL ACQUA WILLIAM (US)
WU YANLI (US)
BEYAZ-KAVUNCU NURTEN (US)
BORROK MARTIN (US)
DALL ACQUA WILLIAM (US)
WU YANLI (US)
BEYAZ-KAVUNCU NURTEN (US)
Application Number:
PCT/US2015/030964
Publication Date:
March 17, 2016
Filing Date:
May 15, 2015
Export Citation:
Assignee:
MEDIMMUNE LLC (US)
International Classes:
A61K39/395; C07K16/00
Foreign References:
| US20070148164A1 | 2007-06-28 |
Other References:
See also references of EP 3142700A4
Attorney, Agent or Firm:
MENSAH, Kwame N. et al. (LLCOne Medlmmune Wa, Gaithersburg MD, US)
Download PDF:
Previous Patent: CELL TRACKING REAGENTS AND THEIR METHODS OF USE
Next Patent: AMPHOTERICIN B DERIVATIVE WITH REDUCED TOXICITY
Next Patent: AMPHOTERICIN B DERIVATIVE WITH REDUCED TOXICITY